
    
      This will be a Phase I, randomized, double-blind, double-dummy, placebo-controlled,
      positive-controlled, single-site study to investigate the effects of therapeutic and
      supratherapeutic oral doses of CBP-307 on the QTc interval in healthy male and female
      subjects. The study is divided into a treatment period of 18 days and a follow-up period of
      12 Â± 2 days.
    
  